1-20 of 30
ms-like tyrosine kinase 3
Close
Sort by
Journal Articles

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Damodaran Narayanan, Olga Pozdnyakova, Robert P. Hasserjian, Sanjay S. Patel, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2021) 5 (11): 2539–2549.
https://doi.org/10.1182/bloodadvances.2021004250
Published: 2021
Includes: Supplemental data
Journal Articles

SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3 -ITD–mutant AML

Suruchi Pacharne, Oliver M. Dovey, Jonathan L. Cooper, Muxin Gu, Mathias J. Friedrich, Sandeep S. Rajan, Maxim Barenboim, Grace Collord, M. S. Vijayabaskar, Hannes Ponstingl, Etienne De Braekeleer, Ruben Bautista, Milena Mazan, Roland Rad, Konstantinos Tzelepis, Penny Wright, Malgorzata Gozdecka, George S. Vassiliou
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2412–2425.
https://doi.org/10.1182/bloodadvances.2020003443
Published: 2021
Includes: Supplemental data
Journal Articles

Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis

David J. Young, Bao Nguyen, Ruiqi Zhu, Jaesung Seo, Li Li, Mark J. Levis, Keith W. Pratz, Amy S. Duffield, Donald Small
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2285–2293.
https://doi.org/10.1182/bloodadvances.2020002876
Published: 2021
Includes: Supplemental data
Journal Articles

ETV6-FLT3– positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML

Clinical Trials & Observations
Barbara Spitzer, Filemon S. Dela Cruz, Glorymar D. Ibanez Sanchez, Yanming Zhang, Wenbin Xiao, Ryma Benayed, Alina Markova, M. Irene Rodriguez-Sanchez, Nancy Bouvier, Mikhail Roshal, Andrew L. Kung, Neerav Shukla
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1899–1902.
https://doi.org/10.1182/bloodadvances.2020003699
Published: 2021
Journal Articles

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Clinical Trials & Observations
Christopher J. Walker, Krzysztof Mrózek, Hatice Gulcin Ozer, Deedra Nicolet, Jessica Kohlschmidt, Dimitrios Papaioannou, Luke K. Genutis, Marius Bill, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Albert de la Chapelle, Clara D. Bloomfield
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1474–1482.
https://doi.org/10.1182/bloodadvances.2020003727
Published: 2021
Includes: Supplemental data
Journal Articles

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Clinical Trials & Observations
Cheryl A. C. Peretz, Lisa H. F. McGary, Tanya Kumar, Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Mark J. Levis, Alexander Perl, Benjamin J. Huang, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1437–1441.
https://doi.org/10.1182/bloodadvances.2020003398
Published: 2021
Includes: Supplemental data
Journal Articles

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs, Eric Eldering, Arnon P. Kater
Journal: Blood Advances
Blood Adv (2021) 5 (3): 913–925.
https://doi.org/10.1182/bloodadvances.2020003768
Published: 2021
Includes: Supplemental data
Journal Articles

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1711–1721.
https://doi.org/10.1182/bloodadvances.2020001449
Published: 2020
Includes: Supplemental data
Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Clinical Trials & Observations
Curtis A. Lachowiez, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Kiran Naqvi, Yesid Alvarado, Musa Yilmaz, Nicholas Short, Maro Ohanian, Sherry R. Pierce, Keyur P. Patel, Wei Qiao, Jing Ning, Koji Sasaki, Koichi Takahashi, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop M. Kantarjian, Marina Konopleva, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1311–1320.
https://doi.org/10.1182/bloodadvances.2019001267
Published: 2020
Includes: Supplemental data
Journal Articles

Gilteritinib: potent targeting of FLT3 mutations in AML

Clinical Trials & Observations
Mark Levis, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1178–1191.
https://doi.org/10.1182/bloodadvances.2019000174
Published: 2020
Journal Articles

The prognostic impact of FLT3 -ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Clinical Trials & Observations
Gunnar Juliusson, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Lars Möllgård, Lovisa Wennström, Petar Antunovic, Jörg Cammenga, Fryderyk Lorenz, Emma Ölander, Vladimir Lj Lazarevic, Martin Höglund
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1094–1101.
https://doi.org/10.1182/bloodadvances.2019001335
Published: 2020
Includes: Supplemental data
Journal Articles

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Clinical Trials & Observations
Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2020) 4 (3): 514–524.
https://doi.org/10.1182/bloodadvances.2019000919
Published: 2020
Includes: Supplemental data
Journal Articles

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD + AML

Silvia Masciarelli, Ernestina Capuano, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Francesca Liccardo, Martyna Śniegocka, Serena Travaglini, Nelida I. Noguera, Alessandra Picardi, Vincenzo Petrozza, Alessandro Fatica, Luca Tamagnone, Maria Teresa Voso, Francesco Lo Coco, Francesco Fazi
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4155–4160.
https://doi.org/10.1182/bloodadvances.2019000540
Published: 2019
Includes: Supplemental data
Journal Articles

Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials

Clinical Trials & Observations
Taylor Bucy, John M. Zoscak, III, Motomi Mori, Uma Borate
Journal: Blood Advances
Blood Adv (2019) 3 (23): 4055–4064.
https://doi.org/10.1182/bloodadvances.2019000532
Published: 2019
Includes: Supplemental data
Journal Articles

Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3 - ITD –positive acute myeloid leukemia

Hyun Don Yun, Sunita Nathan, Melissa Larson, Mohammad J. Hussain, Deborah A. Katz, Ankur Varma, Ira Miller, Celalettin Ustun
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3709–3712.
https://doi.org/10.1182/bloodadvances.2019000775
Published: 2019
Journal Articles

LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Neil Beeharry, Sean Landrette, Sophia Gayle, Marylens Hernandez, Jeff E. Grotzke, Peter R. Young, Paul Beckett, Xuan Zhang, Bing Z. Carter, Michael Andreeff, Stephanie Halene, Tian Xu, Jonathan Rothberg, Henri Lichenstein
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3661–3673.
https://doi.org/10.1182/bloodadvances.2019001068
Published: 2019
Includes: Supplemental data
Journal Articles

Gilteritinib induces differentiation in relapsed and refractory FLT3 -mutated acute myeloid leukemia

Clinical Trials & Observations
Christine M. McMahon, Jonathan Canaani, Bryan Rea, Rachel L. Sargent, Julianne N. Qualtieri, Christopher D. Watt, Jennifer J. D. Morrissette, Martin Carroll, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1581–1585.
https://doi.org/10.1182/bloodadvances.2018029496
Published: 2019
Includes: Supplemental data
Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical Trials & Observations
Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1540–1545.
https://doi.org/10.1182/bloodadvances.2019000090
Published: 2019
Journal Articles

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study

Clinical Trials & Observations
Sarah Wagner, Jayakumar Vadakekolathu, Sarah K. Tasian, Heidi Altmann, Martin Bornhäuser, A. Graham Pockley, Graham R. Ball, Sergio Rutella
Journal: Blood Advances
Blood Adv (2019) 3 (8): 1330–1346.
https://doi.org/10.1182/bloodadvances.2018030726
Published: 2019
Includes: Supplemental data
Journal Articles

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia

Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E. Perl, Martin Carroll
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1061–1072.
https://doi.org/10.1182/bloodadvances.2018029850
Published: 2019
Includes: Supplemental data